Jenburkt Pharmaceuticals Ltd
BSE:524731
Intrinsic Value
Jenburkt Pharmaceuticals Ltd. engages in the manufacture and marketing of pharmaceutical formulations and healthcare products. [ Read More ]
The intrinsic value of one
JENBURPH
stock under the Base Case scenario is
628.41
INR.
Compared to the current market price of 795.95 INR,
Jenburkt Pharmaceuticals Ltd
is
Overvalued by 21%.
Jenburkt Pharmaceuticals Ltd's market capitalization is 3.5B INR.
JENBURPH stock price is 795.95 INR.
JENBURPH stock (628.41 INR) is 21% less than its price (795.95 INR).
JENBURPH stock (535.1 INR) is 33% less than its price (795.95 INR). Open DCF Valuation
JENBURPH stock (721.72 INR) is 9% less than its price (795.95 INR). Open Relative Valuation
JENBURPH has downside potential of 35% compared to the average analyst price target.
Open Wall St Estimates
JENBURPH's ROE (Return on Equity) has increased in the last 3 years from 18% to 19%.
JENBURPH's Revenue has grown by 7% over the past 12 months.
JENBURPH's ROIC (Return on Invested Capital) has decreased in the last 3 years from 27% to 24%.
JENBURPH's Revenue has been growing by 8% per year for the last 3 years.
JENBURPH's ROE (Return on Equity) for the past 12 months is positive and is equal to 19%.
JENBURPH has positive Net Income for the last twelve months.
JENBURPH has positive Operating Income for the last twelve months.
JENBURPH's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 24%.
JENBURPH has positive Free Cash Flow for the last twelve months.
JENBURPH has positive three-year average ROE (Return on Equity): 21%. The company is efficient at transforming stockholders' equity into net income.
JENBURPH has very high three-year average ROIC (Return on Invested Capital): 28%. The company is very efficient at using invested capital to generate operating income.
JENBURPH has positive Gross Profit for the last twelve months.
JENBURPH's D/E (Debt to Equity) is very low and is equal to 0.
JENBURPH's short-term assets (830m INR) exceed its short-term liabilties (159m INR).
JENBURPH's long-term assets (1B INR) exceed its long-term liabilties (195m INR).
JENBURPH has negative Net Debt. This means that the company has more cash and short-term investments (565m INR) than debt (136k INR).
JENBURPH's Altman Z-Score is very high and is equal to 12.04.
JENBURPH earns more than enough operating income (284m INR) to safely cover interest payments on its debt (7m INR).
Valuation Backtest
Jenburkt Pharmaceuticals Ltd
Run backtest to discover the historical profit from buying and selling
JENBURPH
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Jenburkt Pharmaceuticals Ltd
Balance Sheet Decomposition
Jenburkt Pharmaceuticals Ltd
| Current Assets | 830m |
| Cash & Short-Term Investments | 564.9m |
| Receivables | 157.5m |
| Other Current Assets | 107.6m |
| Non-Current Assets | 669.2m |
| Long-Term Investments | 338.8m |
| PP&E | 109m |
| Intangibles | 5.7m |
| Other Non-Current Assets | 215.6m |
| Current Liabilities | 158.8m |
| Accounts Payable | 72.6m |
| Accrued Liabilities | 5.2m |
| Short-Term Debt | 136k |
| Other Current Liabilities | 80.8m |
| Non-Current Liabilities | 36.3m |
| Other Non-Current Liabilities | 36.3m |
Earnings Waterfall
Jenburkt Pharmaceuticals Ltd
|
Revenue
|
1.4B
INR
|
|
Cost of Revenue
|
-313.2m
INR
|
|
Gross Profit
|
1.1B
INR
|
|
Operating Expenses
|
-785.6m
INR
|
|
Operating Income
|
284.5m
INR
|
|
Other Expenses
|
-40m
INR
|
|
Net Income
|
244.5m
INR
|
Free Cash Flow Analysis
Jenburkt Pharmaceuticals Ltd
JENBURPH Profitability Score
Profitability Due Diligence
Jenburkt Pharmaceuticals Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Jenburkt Pharmaceuticals Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
JENBURPH Solvency Score
Solvency Due Diligence
Jenburkt Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Jenburkt Pharmaceuticals Ltd's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
JENBURPH Price Targets Summary
Jenburkt Pharmaceuticals Ltd
According to Wall Street analysts, the average 1-year price target for
JENBURPH
is 520 INR
.
Shareholder Return
JENBURPH Price
Jenburkt Pharmaceuticals Ltd
| Average Annual Return | 12.45% |
| Standard Deviation of Annual Returns | 21.02% |
| Max Drawdown | -48% |
| Market Capitalization | 3.5B INR |
| Shares Outstanding | 4 410 000 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Jenburkt Pharmaceuticals Ltd
Country
Industry
Market Cap
Dividend Yield
Description
Jenburkt Pharmaceuticals Ltd. engages in the manufacture and marketing of pharmaceutical formulations and healthcare products. The company is headquartered in Mumbai, Maharashtra and currently employs 730 full-time employees. The firm offers pharmaceutical products for various therapeutic areas, analgesic and antipyretics anthelmintics, anti-arthritic, anti-diabetics, anti-infectives, antifungals, antimalarials, antiulcerants/antacids, aphrodisiac, consumer division, cough and cold, muscle relaxants neuropathic pain, nutraceuticals and pain management. The firm's product brands include Allerzine tablets, Cartisafe forte MSM tablets, Eberjen Cream and SOL, ECOPROT powder, Frendacid suspension, Fundu tablets, Glajen-E capsules, GLUCOTROL tablets, Jenflam tablets, Lutriben cream, Ornel tablets, Pantazole tablets and others. The firm's manufacturing plant is located in Sihor-Gujarat. The firm's products are exported to approximately 13 countries globally.
Contact
IPO
Employees
Officers
The intrinsic value of one
JENBURPH
stock under the Base Case scenario is
628.41
INR.
Compared to the current market price of 795.95 INR,
Jenburkt Pharmaceuticals Ltd
is
Overvalued by 21%.
You don't have any saved screeners yet
